First Header Logo Second Header Logo

Connection

Tao Ma to Alzheimer Disease

This is a "connection" page, showing publications Tao Ma has written about Alzheimer Disease.
Connection Strength

6.068
  1. Zimmermann HR, Yang W, Kasica NP, Zhou X, Wang X, Beckelman BC, Lee J, Furdui CM, Keene CD, Ma T. Brain-specific repression of AMPKa1 alleviates pathophysiology in Alzheimer's model mice. J Clin Invest. 2020 07 01; 130(7):3511-3527.
    View in: PubMed
    Score: 0.579
  2. Wang X, Zimmermann HR, Lockhart SN, Craft S, Ma T. Decreased Levels of Blood AMPKa1 but not AMPKa2 Isoform in Patients with Mild Cognitive Impairment and Alzheimer's Disease: A Pilot Study. J Alzheimers Dis. 2020; 76(1):217-224.
    View in: PubMed
    Score: 0.559
  3. Day SM, Ma T. Therapeutic Potential of Glucagon-Like Peptide-1 Cleavage Product for Alzheimer's Disease. Neurosci Bull. 2019 Oct; 35(5):934-936.
    View in: PubMed
    Score: 0.528
  4. Beckelman BC, Yang W, Kasica NP, Zimmermann HR, Zhou X, Keene CD, Ryazanov AG, Ma T. Genetic reduction of eEF2 kinase alleviates pathophysiology in Alzheimer's disease model mice. J Clin Invest. 2019 02 01; 129(2):820-833.
    View in: PubMed
    Score: 0.524
  5. Wang X, Zimmermann HR, Ma T. Therapeutic Potential of AMP-Activated Protein Kinase in Alzheimer's Disease. J Alzheimers Dis. 2019; 68(1):33-38.
    View in: PubMed
    Score: 0.522
  6. Beckelman BC, Day S, Zhou X, Donohue M, Gouras GK, Klann E, Keene CD, Ma T. Dysregulation of Elongation Factor 1A Expression is Correlated with Synaptic Plasticity Impairments in Alzheimer's Disease. J Alzheimers Dis. 2016 09 06; 54(2):669-78.
    View in: PubMed
    Score: 0.444
  7. Yang W, Zhou X, Zimmermann HR, Cavener DR, Klann E, Ma T. Repression of the eIF2a kinase PERK alleviates mGluR-LTD impairments in a mouse model of Alzheimer's disease. Neurobiol Aging. 2016 May; 41:19-24.
    View in: PubMed
    Score: 0.427
  8. Beckelman BC, Zhou X, Keene CD, Ma T. Impaired Eukaryotic Elongation Factor 1A Expression in Alzheimer's Disease. Neurodegener Dis. 2016; 16(1-2):39-43.
    View in: PubMed
    Score: 0.420
  9. Ma T, Chen Y, Vingtdeux V, Zhao H, Viollet B, Marambaud P, Klann E. Inhibition of AMP-activated protein kinase signaling alleviates impairments in hippocampal synaptic plasticity induced by amyloid ß. J Neurosci. 2014 Sep 03; 34(36):12230-8.
    View in: PubMed
    Score: 0.386
  10. Ma T. GSK3 in Alzheimer's disease: mind the isoforms. J Alzheimers Dis. 2014; 39(4):707-10.
    View in: PubMed
    Score: 0.369
  11. Ma T, Trinh MA, Wexler AJ, Bourbon C, Gatti E, Pierre P, Cavener DR, Klann E. Suppression of eIF2a kinases alleviates Alzheimer's disease-related plasticity and memory deficits. Nat Neurosci. 2013 Sep; 16(9):1299-305.
    View in: PubMed
    Score: 0.359
  12. Ma T, Du X, Pick JE, Sui G, Brownlee M, Klann E. Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J Neurosci. 2012 Oct 03; 32(40):13701-8.
    View in: PubMed
    Score: 0.338
  13. Ma T, Klann E. Amyloid ß: linking synaptic plasticity failure to memory disruption in Alzheimer's disease. J Neurochem. 2012 Jan; 120 Suppl 1:140-8.
    View in: PubMed
    Score: 0.319
  14. Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK. Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease. PLoS One. 2010 Sep 20; 5(9).
    View in: PubMed
    Score: 0.294
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.